0001140361-19-021751.txt : 20191202 0001140361-19-021751.hdr.sgml : 20191202 20191202080014 ACCESSION NUMBER: 0001140361-19-021751 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20191202 DATE AS OF CHANGE: 20191202 EFFECTIVENESS DATE: 20191202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 191262081 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 25 1 form25.htm 25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 25
 
NOTIFICATION OF REMOVAL FROM LISTING AND/OR
REGISTRATION UNDER SECTION 12(b) OF THE
SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 001-34912
 
Celgene Corporation
NASDAQ Global Market
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
 
86 Morris Avenue, Summit, New Jersey, 07901
(908) 673-9000
 (Address, including zip code, and telephone number, including area code,
of Issuer’s principal executive offices)
 
Contingent Value Rights
(Description of class of securities)
 
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

☐
17 CFR 240.12d2-2(a)(1)

☐
17 CFR 240.12d2-2(a)(2)

☐
17 CFR 240.12d2-2(a)(3)

☐
17 CFR 240.12d2-2(a)(4)

☐
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

☒
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, Celgene Corporation certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
 
DATE: December 2, 2019
BY:
/s/ Katherine R. Kelly

Name:
 Katherine R. Kelly

Title:
 Secretary

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable.  See General Instructions.